In this episode of AMCP Unscripted, host Amy Lugo, PharmD, BCPS, BC-ADM, FAPhA, FAMCP, Founder and CEO of LoneStar Health Solutions, is joined by Dr. Joshua Lennon, Assistant Professor at the University of Tennessee Health Science Center, to discuss the unique challenges of diagnosing and treating narcolepsy in children. They explore why pediatric narcolepsy is frequently misdiagnosed, the significant delays many patients experience before receiving an accurate diagnosis, and the impact untreated symptoms can have on learning, social development, and long-term health. The conversation also examines current FDA-approved treatment options, promising advances in orexin-targeted therapies, and the important role managed care professionals play in improving timely access to evidence-based care for children living with narcolepsy.
On February 23, 2026, the U.S. Food and Drug Administration (FDA) released draft guidance outlining a new regulatory framework to support approval of individualized therapies for ultra-rare diseases when randomized controlled trials are infeasible because of extremely small patient populations.
These disease state webinars are sponsored, developed and presented by PRIME.
Sponsored webinar that discussed the importance of biomarker testing for metastatic non-small cell lung cancer.
Sponsored webinar that introduced a new treatment for chronic graft-versus-host disease (cGVHD).
Sponsored webinar that introduced a new treatment for chronic graft-versus-host disease (cGVHD).
Sponsored webinar that discussed the urgency needed to diagnose lupus nephritis as early as possible, and the multidisciplinary care needed in patient management to prevent irreversible kidney damage and progression to end-stage renal disease (ESRD).
Sponsored webinar that discussed the urgency needed to diagnose lupus nephritis as early as possible, and the multidisciplinary care needed in patient management to prevent irreversible kidney damage and progression to end-stage renal disease (ESRD).
Sponsored webinar that provided insights into the "hidden" burden of Systemic Lupus Erythematosus (SLE): a multisystemic autoimmune disease.
Sponsored webinar that discussed topics such as, the RNAi overview, the disease burden of PH1, PH2 and PH3, and an RNAi technology as a potential treatment approach for this rare condition.
Sponsored webinar that discussed topics such as, the RNAi overview, the disease burden of PH1, PH2 and PH3, and an RNAi technology as a potential treatment approach for this rare condition.
Sponsored webinar that reframed the landscape of Chemotherapy-induced myelosuppression (CIM) with a fresh perspective on the root of the clinical problem, the patient burden revealed through real world management of CIM, and the hope for a future that fulfills the unmet need – one made more complicated by the confounding influence of Covid-19 in the day-to-day management of people facing malignancy.